Am J Perinatol 2017; 34(08): 729-734
DOI: 10.1055/s-0036-1597994
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

GSTP1 and CYP2B6 Genetic Polymorphisms and the Risk of Bronchopulmonary Dysplasia in Preterm Neonates

Sophia Zachaki*
1   Genesis Genoma Lab, Genetic Diagnosis, Clinical Genetics and Research, Athens, Greece
,
Aggeliki Daraki*
2   Laboratory of Health Physics, Radiobiology and Cytogenetics, National Center for Scientific Research “Demokritos,” Athens, Greece
,
Elena Polycarpou
3   Neonatal Intensive Unit, General District Hospital Athens “Alexandra,” Athens, Greece
,
Chrysa Stavropoulou
2   Laboratory of Health Physics, Radiobiology and Cytogenetics, National Center for Scientific Research “Demokritos,” Athens, Greece
,
Kalliopi N. Manola
2   Laboratory of Health Physics, Radiobiology and Cytogenetics, National Center for Scientific Research “Demokritos,” Athens, Greece
,
Stavroula Gavrili
3   Neonatal Intensive Unit, General District Hospital Athens “Alexandra,” Athens, Greece
› Institutsangaben
Weitere Informationen

Publikationsverlauf

24. Oktober 2016

09. Dezember 2016

Publikationsdatum:
12. Januar 2017 (online)

Abstract

Objectives Antioxidant response plays a key role in bronchopulmonary dysplasia (BPD) pathogenesis. The glutathione-S-tranferases pi 1 (GSTP1) and cytochrome P450 (CYP) detoxification enzymes protect cells from oxidative damage. The aim of the study was to investigate whether the A313G GSTP1 and G516T CYP2B6 inactivating polymorphisms could be associated with BPD susceptibility.

Study Design To test this hypothesis, we conducted a case–control study enrolled 138 premature neonates ≤32 weeks of gestational age; of the 138, 46 developed BPD and 92 did not develop BPD. Genomic deoxyribonucleic acid was extracted from neonates' peripheral blood and was used as template for GSTP1 and CYP2B6 genotyping using the real-time polymerase chain reaction method.

Results Our report provides evidence for a possible pathogenetic role of the G516T CYP2B6 polymorphism in BPD susceptibility. Although no differences in the frequencies of the GSTP1 variant genotypes were noticed between premature neonates who developed BPD and neonates who did not develop BPD, a significantly higher frequency of the GSTP1 polymorphism was observed in extremely low birth weight infants. Despite the small sample size, it is very interesting the fact that all neonates ≤1,000 g carrying the homozygous mutant GSTP1 genotype developed BPD.

Conclusion Our results underscore the significance of both CYP2B6 and GSTP1 polymorphisms in modulating the risk of BPD.

* Both the authors equally contributed to the study.


 
  • References

  • 1 Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006; 367 (9520): 1421-1431
  • 2 Northway Jr WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276 (07) 357-368
  • 3 O'Brodovich HM, Stalcup SA, Pang LM, Lipset JS, Mellins RB. Retraction. Bradykinin production and increased pulmonary endothelial permeability during acute respiratory failure in unanesthetized sheep. J Clin Invest 1985; 75 (05) 1747 . Doi: 10.1172/JCI110061
  • 4 Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357 (19) 1946-1955
  • 5 Ambalavanan N, Cotten CM, Page GP. , et al; Genomics and Cytokine Subcommittees of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Integrated genomic analyses in bronchopulmonary dysplasia. J Pediatr 2015; 166 (03) 531-537.e13
  • 6 Somaschini M, Castiglioni E, Presi S, Volonteri C, Ferrari M, Carrera P. Genetic susceptibility to neonatal lung diseases. Acta Biomed 2012; 83 (Suppl. 01) 10-14
  • 7 Sampath V, Garland JS, Helbling D. , et al. Antioxidant response genes sequence variants and BPD susceptibility in VLBW infants. Pediatr Res 2015; 77 (03) 477-483
  • 8 Gavrili S, Zachaki S, Daraki A. , et al. Association of C609T-inborn polymorphism of NAD(P)H: quinone oxidoreductase 1 with the risk of bronchopulmonary dysplasia in preterm neonates. Am J Perinatol 2016; 33 (06) 535-539
  • 9 Singh S. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother Pharmacol 2015; 75 (01) 1-15
  • 10 Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272 (15) 10004-10012
  • 11 Watson MA, Stewart RK, Smith GBJ, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19 (02) 275-280
  • 12 Lang T, Klein K, Fischer J. , et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11 (05) 399-415
  • 13 Xu C, Ogburn ET, Guo Y, Desta Z. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos 2012; 40 (04) 717-725
  • 14 Hofmann MH, Blievernicht JK, Klein K. , et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008; 325 (01) 284-292
  • 15 Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163 (07) 1723-1729
  • 16 Ehrenkranz RA, Walsh MC, Vohr BR. , et al; National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116 (06) 1353-1360
  • 17 Zachaki S, Stavropoulou C, Kalomoiraki M. , et al. Association of A(313)G glutathione S-transferase P1 germline polymorphism with susceptibility to de novo myelodysplastic syndrome. Leuk Lymphoma 2013; 54 (08) 1756-1761
  • 18 Buczynski BW, Maduekwe ET, O'Reilly MA. The role of hyperoxia in the pathogenesis of experimental BPD. Semin Perinatol 2013; 37 (02) 69-78
  • 19 Karagianni P, Rallis D, Fidani L. , et al. Glutathion-S-Transferase P1 polymorphisms association with broncopulmonary dysplasia in preterm infants. Hippokratia 2013; 17 (04) 363-367
  • 20 Daraki A, Zachaki S, Koromila T. , et al. The G516T CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalities. PLoS One 2014; 9 (02) e88879 . Doi: 10.1371/journal.pone.0088879
  • 21 Yu KH, Li J, Snyder M, Shaw GM, O'Brodovich HM. The genetic predisposition to bronchopulmonary dysplasia. Curr Opin Pediatr 2016; 28 (03) 318-323
  • 22 Li J, Yu KH, Oehlert J. , et al. Exome sequencing of neonatal blood spots and the identification of genes implicated in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2015; 192 (05) 589-596
  • 23 Lal CV, Ambalavanan N. Genetic predisposition to bronchopulmonary dysplasia. Semin Perinatol 2015; 39 (08) 584-591